1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. FUSN PHAR
  6. News
  7. Summary
    FUSN   CA36118A1003

FUSN PHAR

(FUSN)
  Report
Delayed Nasdaq  -  05/23 02:28:30 pm EDT
3.835 USD   -0.88%
05/11Fusion Pharmaceuticals to Present at the Guggenheim Securities Radiopharmaceuticals Day
PR
05/11Fusion Pharmaceuticals to Present at the Guggenheim Securities Radiopharmaceuticals Day
AQ
05/10Wedbush Adjusts Price Target for Fusion Pharmaceuticals to $19 From $20, Maintains Outperform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Fusion Pharmaceuticals to Present at the B. Riley Securities 2022 Virtual Oncology Conference

01/21/2022 | 08:31am EDT

HAMILTON, ON and BOSTON, Jan. 21, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in a fireside chat at the B. Riley Securities 2022 Virtual Oncology Conference on Thursday, January 27, 2022 at 2:00 p.m. ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.

A webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.  

About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear™ linker technology, Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434 targeting insulin-like growth factor 1 receptor, is currently in a Phase 1 clinical trial. The pipeline includes FPI-1966, targeting the fibroblast growth factor receptor 3 (FGFR3), advancing to a Phase 1 study following the investigational new drug (IND) clearance; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1). In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Repair Inhibitors (DDRis) and immuno-oncology agents. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. Fusion and Hamilton, Ontario-based McMaster University are building a current Good Manufacturing Practice (GMP) compliant radiopharmaceutical manufacturing facility designed to support manufacturing of the Company's growing pipeline of TATs.

 

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-b-riley-securities-2022-virtual-oncology-conference-301465560.html

SOURCE Fusion Pharmaceuticals Inc.


© PRNewswire 2022
All news about FUSN PHAR
05/11Fusion Pharmaceuticals to Present at the Guggenheim Securities Radiopharmaceuticals Day
PR
05/11Fusion Pharmaceuticals to Present at the Guggenheim Securities Radiopharmaceuticals Day
AQ
05/10Wedbush Adjusts Price Target for Fusion Pharmaceuticals to $19 From $20, Maintains Outp..
MT
05/10FUSION PHARMACEUTICALS INC. Management's Discussion and Analysis of Financial Conditio..
AQ
05/10Fusion Pharmaceuticals Announces First Quarter 2022 Financial Results and Clinical Prog..
PR
05/10Earnings Flash (FUSN) FUSION PHARMACEUTICALS Reports Q1 Loss $-0.46
MT
05/10Fusion Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March ..
CI
05/04Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
04/26Fusion Pharmaceuticals to Present at the 2022 Bloom Burton & Co. Healthcare Investor Co..
AQ
04/13FUSION PHARMACEUTICALS INC. : Other Events (form 8-K)
AQ
More news
Analyst Recommendations on FUSN PHAR
More recommendations